The Top 5 Biosimilars Articles for the Week of April 8

The Center for Biosimilars® recaps the top news for the week of April 8, 2019.
April 12, 2019


Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of April 8.

Number 5:  Coherus BioSciences announced that its Udenyca sales for the past quarter are expected to be in the range of $36 million to $38 million.

Number 4: An advocacy group for patients with breast cancer in Canada recently published a series of recommendations after convening roundtable discussions with both patients and providers.

Number 3: During this week’s Congress of the Asia Pacific League of Associations for Rheumatology and Australian Rheumatology Association, multiple groups of researchers are reporting on the real-world use of biosimilars in rheumatology.

Number 2:  Pfizer has launched its biosimilar trastuzumab, Trazimera, in Spain. 

Number 1: Genentech has filed a new lawsuit over a proposed bevacizumab biosimilar.

Finally, last week, our e-newsletter asked whether you think drug makers will continue to invest in biosimilars in the long term.

To view results of the poll, visit us on LinkedIn.

To read all of these articles and more, visit 



Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.